フルテキストファイル
著者
本田 正史 Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University 研究者総覧 KAKEN
木村 有佑 Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University 研究者総覧
Teraoka, Shogo Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University
川本 文弥 Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University 研究者総覧 KAKEN
森實 修一 Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University 研究者総覧 KAKEN
引田 克弥 Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University 研究者総覧 KAKEN
武中 篤 Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University 研究者総覧 KAKEN
キーワード
benign prostatic hyperplasia
combination treatment
phosphodiesterase type 5 inhibitor
storage symptoms
β3-adrenoreceptor agonist
抄録
Background: The aim of this study is to evaluate the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, plus mirabegron, a β3-adrenoreceptor agonist, in patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment. Methods: The registration of this study started in August 2016 and ended in July 2019. The inclusion criteria included patients aged ? 50 years who were diagnosed with benign prostatic hyperplasia and who presented with overactive bladder symptoms. Patients were treated with oral tadalafil 5 mg once daily for 4 weeks. Then, its efficacy was evaluated. Patients who responded to the treatment received oral tadalafil 5 mg once daily for 4 more weeks (monotreatment group). Meanwhile, those who did not respond received oral tadalafil 5 mg and mirabegron 50 mg, which is an add-on treatment, once daily for 4 more weeks (combination therapy group). Results: After 8 weeks, the monotreatment group (n = 19) and the combination group (n = 56) had significantly better total Overactive Bladder Symptom Score and International Prostate Symptom Score and International Prostate Symptom Score voiding and storage subscale scores. Moreover, the two groups experienced significant improvements in the total Overactive Bladder Questionnaire and Nocturia Quality of Life Questionnaire scores, and Nocturia Quality of Life Questionnaire Bother/Concern subscale score after 8 weeks. However, there were no cases of urinary retention or serious adverse events. Conclusion: Combination treatment with tadalafil and mirabegron is effective and safe for patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment. Hence, tadalafil plus mirabegron is a promising therapeutic option, and it can improve overactive bladder related-quality of life.
出版者
Tottori University Medical Press
資料タイプ
学術雑誌論文
外部リンク
ISSN
05135710
EISSN
13468049
書誌ID
AA00892882
掲載誌名
Yonago Acta Medica
最新掲載誌名
Yonago Acta Medica
65
3
開始ページ
231
終了ページ
237
発行日
2022-08-29
出版者DOI
著者版フラグ
出版社版
著作権表記
(C) 2022 Tottori University Medical Press.
掲載情報
Yonago Acta Medica. 2022, 65(3), 231-237. doi10.33160/yam.2022.08.009
部局名
医学部・医学系研究科・医学部附属病院
言語
英語